Events

• Relonova®, new Russian drug for the relief of migraine-associated headaches, is now available in online pharmacies

  12 September 2023

  

  A new Russian drug for the relief of headaches caused by migraine attacks, Relonova^® (INN Rizatriptan), developed and produced by the Russian pharmaceutical company NovaMedica, has become available for purchase on online pharmacy websites, which will make it easier for patients to access it.

• Production of one of the world's most sought-after drugs for migraine therapy starts in Moscow

  12 July 2023

  

  The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.

• NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world

  21 March 2023

  

  March 21, 2023, Moscow – Russian pharmaceutical company NovaMedica (investment project of RUSNANO) registered its own-development product Relonova (INN Rizatriptan) for migraine-related headache relief. This is the first Rizatriptan-based drug in Russia that is fully localized in the country, from development to manufacturing and introduction in prescription practice. Relonova will be manufactured in Moscow at the Technological Center NovaMedica Innotech (100% subsidiary of NovaMedica), which will enable uninterrupted supplies of the drug and its availability for Russian patients.

• NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world

  15 December 2022

  

  Russian pharmaceutical company NovaMedica (RUSNANO portfolio company) has developed and registered two innovative drugs to combat disorders of the central nervous system (CNS): Difendum® for pain relief and Levroso® Long for insomnia therapy. The products will be manufactured in Russia by the Technology Center NovaMedica Innotech (100% subsidiary of NovaMedica).

• GXP News Contest takes competitors to R&D Center

  25 August 2022

  

  R&D Center NovaMedica Innotech welcomed finalists of the contest among authors of opinion columns on drug development in Russia Anastasia Novikova, Alexey Veselkov and Maria Lobanova. The contest was organized by the leading website on pharmaceutics GxP News.

• R&D Center NovaMedica Innotech becomes industrial partner of the Eurasian Academy of Good Practices

  17 June 2022

  

  R&D Center NovaMedica Innotech (subsidiary of the pharma company NovaMedica, RUSNANO portfolio asset) and the independent non-profit organization Eurasian Academy of Good Practices signed the Memorandum of Cooperation aiming to develop competences of the Russian pharmaceutics professionals.

• R&D Center NovaMedica Innotech ready to double the capacity of pharmaceutical research and manufacturing projects

  12 May 2022

  

  R&D Center NovaMedica Innotech has celebrated its 5th anniversary. The Center was created during implementation of the R&D strategy of its parent company NovaMedica (RUSNANO’s portfolio asset), which is 10 years old this year. Innotech does projects under NovaMedica’s own R&D program and offers to its partners services in development of new drugs and in contract manufacturing of solid dosage forms.

• NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease

  19 April 2022

  

  Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name MIOREOL®. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.

• Timofey Petrov appointed Director General of Innotech

  25 October 2021

  

  Russian pharmaceutical company NovaMedica announces appointment of Timofey PETROV as the head of the R&D Center NovaMedica Innotech (subsidiary of NovaMedica).

• Innotech renews manufacturing license

  21 September 2021

  

  R&D Center NovaMedica Innotech has successfully passed the audit of the Ministry of Industry and Trade and received a renewed and extended manufacturing license for production of pharmaceutical drugs, which creates new contracting opportunities and, in addition to the already existing services, allows carrying out primary and secondary packaging of biological products.